"name","instanceType","label","rationale","description","id","uuid:ID"
"Study Design 1","StudyDesign","","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign_1","c59dcd55-7704-4105-9a09-0794f3eb6b09"
